Delphi Management Partners VIII, L.L.C. 13F-HR Quarterly holdings report by institutional manager

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL

OMB Number:		3235-0006
Expires:	Oct 31, 2018
Estimated average burden
hours per response:		23.8

COLUMN 1	COLUMN 2	COLUMN 3	COLUMN 4	COLUMN 5			COLUMN 6	COLUMN 7	COLUMN 8
			VALUE	SHRS OR	SH/	PUT/	INVESTMENT	OTHER	VOTING AUTHORITY
NAME OF ISSUER	TITLE OF CLASS	CUSIP	(x$1000)	PRN AMT	PRN	CALL	DISCRETION	MANAGER	SOLE	SHARED	NONE
Calithera Biosciences, Inc.	Common Stock	13089P101	5,072	2,426,702	SH		SOLE		2,426,702	0	0
Karyopharm Therapeutics, Inc.	Common Stock	48576U106	23,354	2,263,006	SH		SOLE		2,263,006	0	0
Mereo BioPharma Group PLC	ADS	589492107	814	256,734	SH		SOLE		256,734	0	0
Tandem Diabetes, Inc.	Common Stock	875372203	97,400	1,000,000	SH		SOLE		1,000,000	0	0